NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Exclusion Criteria

• •Active infection
• •Presence of known metastases (stage IV disease)
• •Pregnant or lactating women
• •Prior chemotherapy or radiation therapy for the primary breast cancer
• •Concomitant malignancies or previous malignancies within the last 5 years except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
• •History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias
• •Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary or metabolic disease including diabetes, wound healing disorders, ulcers or bone fractures)
• •Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipated need for major surgery during the course of study treatment
• •Current known infection with Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) or Hepatitis C Virus (HCV)
• •Receipt of intravenous antibiotics for infection within 14 days prior to receiving study treatment
• •Current chronic daily treatment with corticosteroids (dose \>10 mg/day methylprednisolone equivalent) except inhaled steroids
• •Known hypersensitivity to any of the study drugs
• •Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol